A Phase 3 interventional study of NewGam in Primary Thrombocytopenia, sponsored by Octapharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-06-07.
Sponsored by Octapharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic — 3 open to participants now, 3 under way, 1 of them phase 3. Immunoglobulins, Intravenous · Purpura, Thrombocytopenic, Idiopathic.
Among the 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic, this one is the 7th largest by enrollment, is the only one that started in 2011, is one of 9 in phase 3, and was the 8th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →3 of the 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic are open now, in 9 countries. Recruiting first, the newest first:
Kedrion S.p.A. · Sites in United States, Czechia, Germany and 5 more countries
Ages 18–70
Peking University People's Hospital · Sites in China
Ages 18–50 · Women only
Fujian Medical University Union Hospital · Sites in China
Ages 29 days–14 yrs
By country, each count listing its studies:
Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 40 across the 13 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 13 have an industry lead sponsor. The 10 most frequent:
Octapharma is the lead sponsor of 71 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 16 (94%) have results posted.
Octapharma has 3 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
1 of the studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059000Phase 3Kedrion S.p.A.A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing Immunoglobulins, Intravenous in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
NewGam is a newly developed human normal immunoglobulin solution for intravenous administration (IGIV). This study will evaluate the safety and efficacy of NewGam 10% in patients with primary immune thrombocytopenia.
The primary objective of the study is to assess the efficacy of NewGam in correcting the platelet count. The secondary objective of the study is to evaluate the safety of NewGam. Safety will be assessed by monitoring vital signs, physical examination, evaluation of adverse events (AE) and laboratory parameters, and viral safety testing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Administration of intravenous immunoglobulin (IGIV), anti-D immunoglobulin or thrombopoietin receptor agonists, or other enhancing drugs (including or other immunomodulatory drugs) within 3 weeks before enrollment, except for:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each participant received 1 g/kg NewGam intravenously on 2 consecutive days.
Drug: NewGam
NewGam is a solution of human normal immunoglobulin 10% treated with solvent/detergent and nanofiltered for intravenous administration.
Percentage of Responders
A responder is a study participant with an increase in platelets to ≥ 50x10\^9/L within 7 days after the first infusion, ie, by study Day 8.
Time frame: Day 1 to Day 8
Percentage of Alternative Responders
An alternative responder is a study participant with an increase in platelets to ≥ 30x10\^9/L and to at least double the baseline platelet count, confirmed on at least 2 occasions at least 7 days apart, and absence of bleeding.
Time frame: Day 1 to Day 22
Percentage of Complete Responders
A complete responder is a study participant with an increase in platelets to ≥ 100x10\^9/L, confirmed on at least 2 occasions at least 7 days apart, and absence of bleeding.
Time frame: Day 1 to Day 22
Percentage of Alternative Responders Who Lost the Response
An alternative responder who lost the response is a study participant who met the criterion for an alternative response but who then deteriorated, ie, their platelet count decreased to \< 30x10\^9/L, their platelet count decreased to less than double the baseline count, or bleeding occurred.
Time frame: Day 1 to Day 22
Percentage of Complete Responders Who Lost the Response
A complete responder who lost the response is a study participant who met the criterion for a complete response but who then deteriorated, ie, their platelet count decreased to \< 100x10\^9/L or bleeding occurred.
Time frame: Day 1 to Day 22
Time to a Response
A study participant had a response if their platelets increased to ≥ 50x10\^9/L within 7 days after the first infusion, ie, by study Day 8.
Time frame: Day 1 to Day 8
Time to an Alternative Response
A study participant had a response if their platelets increased to ≥ 30x10\^9/L and to at least double the baseline platelet count, confirmed on at least 2 occasions at least 7 days apart, and absence of bleeding.
Time frame: Day 1 to Day 22
Time to a Complete Response
A study participant had a complete response if their platelets increased to ≥ 100x10\^9/L, confirmed on at least 2 occasions at least 7 days apart, and absence of bleeding.
Time frame: Day 1 to Day 22
Duration of a Response
The duration of a response was defined as the time from when a response was achieved until the platelet count fell below 50x10\^9/L.
Time frame: Day 1 to Day 22
Duration of an Alternative Response
The duration of an alternative response was defined as the time from when an alternative response was achieved until the platelet count fell below 50x10\^9/L.
Time frame: Day 1 to Day 22
Duration of a Complete Response
The duration of a complete response was defined as the time from when a complete response was achieved until the platelet count fell below 50x10\^9/L.
Time frame: Day 1 to Day 22
Platelet Count by Visit
The platelet count at each study visit are presented.
Time frame: Day 1 to Day 22
Maximum Platelet Count
The maximum platelet count achieved during the study is presented.
Time frame: Day 1 to Day 22
Percentage of Responders Who Achieved a Normal Platelet Count
The percentage of responders who achieved a normal platelet count is presented.
Time frame: Day 1 to Day 22
Bleeding Intensity
The percentage of participants with various intensities of overall bleeding, epistaxis (bleeding of the nose), oral bleeding, and skin bleeding graded as none, minor, mild, moderate, or severe at Baseline and Day 22 are reported.
Time frame: Day 1 to Day 22
Percentage of Participants Who Achieved a Platelet Count > 30x10^9/L
The percentage of participants who achieved a platelet count \> 30x10\^9/L within 1 and 2 days after infusion is reported.
Time frame: Day 1 to Day 2
| Milestone | NewGam |
|---|---|
| Started | 40 |
| Completed | 31 |
| Not completed | 9 |
| Withdrew: Investigator judgement | 3 |
| Withdrew: Death | 2 |
| Withdrew: Withdrawal by patient | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 1 |
A responder is a study participant with an increase in platelets to ≥ 50x10\^9/L within 7 days after the first infusion, ie, by study Day 8.
| Percentage of participants | NewGam |
|---|---|
| Percentage of Responders | 80.6 (63.98 to 91.81) |
An alternative responder is a study participant with an increase in platelets to ≥ 30x10\^9/L and to at least double the baseline platelet count, confirmed on at least 2 occasions at least 7 days apart, and absence of bleeding.
| Percentage of participants | NewGam |
|---|---|
| Percentage of Alternative Responders | 66.7 (49.03 to 81.44) |
A complete responder is a study participant with an increase in platelets to ≥ 100x10\^9/L, confirmed on at least 2 occasions at least 7 days apart, and absence of bleeding.
| Percentage of participants | NewGam |
|---|---|
| Percentage of Complete Responders | 50.0 (32.92 to 67.08) |
An alternative responder who lost the response is a study participant who met the criterion for an alternative response but who then deteriorated, ie, their platelet count decreased to \< 30x10\^9/L, their platelet count decreased to less than double the baseline count, or bleeding occurred.
| Percentage of participants | NewGam |
|---|---|
| Percentage of Alternative Responders Who Lost the Response | 45.8 (25.55 to 67.18) |
A complete responder who lost the response is a study participant who met the criterion for a complete response but who then deteriorated, ie, their platelet count decreased to \< 100x10\^9/L or bleeding occurred.
| Percentage of participants | NewGam |
|---|---|
| Percentage of Complete Responders Who Lost the Response | 77.8 (52.36 to 93.49) |
A study participant had a response if their platelets increased to ≥ 50x10\^9/L within 7 days after the first infusion, ie, by study Day 8.
| Days | NewGam |
|---|---|
| Time to a Response | 2.0 (1.00 to 2.00) |
A study participant had a response if their platelets increased to ≥ 30x10\^9/L and to at least double the baseline platelet count, confirmed on at least 2 occasions at least 7 days apart, and absence of bleeding.
| Days | NewGam |
|---|---|
| Time to an Alternative Response | 1.0 (1.00 to 2.00) |
A study participant had a complete response if their platelets increased to ≥ 100x10\^9/L, confirmed on at least 2 occasions at least 7 days apart, and absence of bleeding.
| Days | NewGam |
|---|---|
| Time to a Complete Response | 2.0 (2.00 to 2.00) |
The duration of a response was defined as the time from when a response was achieved until the platelet count fell below 50x10\^9/L.
| Days | NewGam |
|---|---|
| Duration of a Response | 14.0 (10.00 to 17.00) |
The duration of an alternative response was defined as the time from when an alternative response was achieved until the platelet count fell below 50x10\^9/L.
| Days | NewGam |
|---|---|
| Duration of an Alternative Response | 18.5 (17.00 to 20.00) |
The duration of a complete response was defined as the time from when a complete response was achieved until the platelet count fell below 50x10\^9/L.
| Days | NewGam |
|---|---|
| Duration of a Complete Response | 12.5 (10.00 to 16.00) |
The platelet count at each study visit are presented.
| 10^9 platelets/L | NewGam |
|---|---|
| Baseline | 8.8 ± 5.76 |
| Day 2 | 41.6 ± 31.41 |
| Day 3 | 115.0 ± 85.58 |
| Day 4 | 154.6 ± 118.04 |
| Day 5 | 168.2 ± 149.89 |
| Day 6 | 179.3 ± 178.64 |
| Day 7 | 206.3 ± 195.75 |
| Day 8 | 186.5 ± 205.44 |
| Day 15 | 88.1 ± 130.07 |
| Day 22/End of treatment | 41.4 ± 65.48 |
The maximum platelet count achieved during the study is presented.
| 10^9 platelets/L | NewGam |
|---|---|
| Maximum Platelet Count | 236.9 ± 205.18 |
The percentage of responders who achieved a normal platelet count is presented.
| Percentage of participants | NewGam |
|---|---|
| Percentage of Responders Who Achieved a Normal Platelet Count | 79.3 (60.28 to 92.01) |
The percentage of participants with various intensities of overall bleeding, epistaxis (bleeding of the nose), oral bleeding, and skin bleeding graded as none, minor, mild, moderate, or severe at Baseline and Day 22 are reported.
| Percentage of participants | NewGam |
|---|---|
| Overall - Total - Baseline | 100.0 |
| Overall - Total - Day 8 | 100.0 |
| Overall - Total - Day 22 | 100.0 |
| Overall - None - Baseline | 36.1 |
| Overall - None - Day 8 | 91.2 |
| Overall - None - Day 22 | 72.2 |
| Overall - Minor - Baseline | 38.9 |
| Overall - Minor - Day 8 | 5.9 |
| Overall - Minor - Day 22 | 19.4 |
| Overall - Mild - Baseline | 5.6 |
| Overall - Mild - Day 8 | 2.9 |
| Overall - Mild - Day 22 | 2.8 |
| Overall - Moderate - Baseline | 19.4 |
| Overall - Moderate - Day 8 | 0.0 |
| Overall - Moderate - Day 22 | 2.8 |
| Overall - Severe - Baseline | 0.0 |
| Overall - Severe - Day 8 | 0 |
| Overall - Severe - Day 22 | 2.8 |
| Epistaxis - Total - Baseline | 100.0 |
| Epistaxis - Total - Day 22 | 100.0 |
| Epistaxis - None - Baseline | 83.3 |
| Epistaxis - None - Day 22 | 91.7 |
| Epistaxis - Minor - Baseline | 8.3 |
| Epistaxis - Minor - Day 22 | 8.3 |
| Epistaxis - Mild - Baseline | 5.6 |
| Epistaxis - Mild - Day 22 | 0.0 |
| Epistaxis - Moderate - Baseline | 2.8 |
| Epistaxis - Moderate - Day 22 | 0.0 |
| Epistaxis - Severe - Baseline | 0.0 |
| Epistaxis - Severe - Day 22 | 0.0 |
| Oral bleeding - Total - Baseline | 100.0 |
| Oral bleeding - Total - Day 22 | 100.0 |
| Oral bleeding - None - Baseline | 75.0 |
| Oral bleeding - None - Day 22 | 86.1 |
| Oral bleeding - Minor - Baseline | 13.9 |
| Oral bleeding - Minor - Day 22 | 8.3 |
| Oral bleeding - Mild - Baseline | 0.0 |
| Oral bleeding - Mild - Day 22 | 2.8 |
| Oral bleeding - Moderate - Baseline | 5.6 |
| Oral bleeding - Moderate - Day 22 | 2.8 |
| Oral bleeding - Severe - Baseline | 5.6 |
| Oral bleeding - Severe - Day 22 | 0.0 |
| Skin bleeding - Total - Baseline | 100.0 |
| Skin bleeding - Total - Day 22 | 100.0 |
| Skin bleeding - None - Baseline | 41.7 |
| Skin bleeding - None - Day 22 | 77.8 |
| Skin bleeding - Minor - Baseline | 25.0 |
| Skin bleeding - Minor - Day 22 | 22.2 |
| Skin bleeding - Mild - Baseline | 27.8 |
| Skin bleeding - Mild - Day 22 | 0.0 |
| Skin bleeding - Moderate - Baseline | 5.6 |
| Skin bleeding - Moderate - Day 22 | 0.0 |
| Skin bleeding - Severe - Baseline | 0.0 |
| Skin bleeding - Severe - Day 22 | 0.0 |
The percentage of participants who achieved a platelet count \> 30x10\^9/L within 1 and 2 days after infusion is reported.
| Percentage of participants | NewGam |
|---|---|
| Day 1 | 55.0 |
| Day 2 | 77.5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NewGam | — | 6/40 (15%) | 30/40 (75%) |
| Event | NewGam |
|---|---|
| Autoimmune thrombocytopeniaBlood and lymphatic system disorders | 3/40 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/40 |
| DysphagiaGastrointestinal disorders | 1/40 |
| Cerebral haematomaNervous system disorders | 1/40 |
| Meningitis asepticNervous system disorders | 1/40 |
| PneumoniaInfections and infestations | 1/40 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/40 |
| SepsisInfections and infestations | 1/40 |
| Event | NewGam |
|---|---|
| HeadacheNervous system disorders | 17/40 |
| PyrexiaGeneral disorders | 9/40 |
| Autoimmune thrombocytopeniaBlood and lymphatic system disorders | 6/40 |
| NauseaGastrointestinal disorders | 6/40 |
| AnaemiaBlood and lymphatic system disorders | 5/40 |
| VomitingGastrointestinal disorders | 4/40 |
| DizzinessNervous system disorders | 3/40 |
| Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders | 2/40 |
| AstheniaGeneral disorders | 2/40 |
| ChillsGeneral disorders | 2/40 |
Safety set: All participants enrolled in the study who received at least part of 1 dose of NewGam.
| Age, Continuous(years) | NewGam |
|---|---|
| Mean | 36.7 ± 15.34 |
| Sex: Female, Male(Participants) | NewGam |
|---|---|
| Female | 17 |
| Male | 23 |
The record gives a start of Oct 2011, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 3 years 11 months after primary completion. A results delay was requested in Jun 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous
Purpura, Thrombocytopenic, Idiopathic →